Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson’s disease model - Itakura, Masanori; Kohda, Tomoko; Kubo, Takeya; Semi, Yuko; Azuma, Yasu-Taka; Nakajima, Hidemitsu; Kozaki, Shunji; Takeuchi, Tadayoshi (Biochemical and biophysical research communications, 2014)
Keywords: Acetylcholine; adverse effects; Animals; Botulinum neurotoxin; botulinum toxin; Botulinum Toxins, Type A - administration & dosage; Botulinum Toxins, Type A - adverse effects; Choline O-Acetyltransferase - metabolism; Corpus Striatum - drug effects; Corpus Striatum - metabolism; disease models; Disease Models, Animal; Female; Male; memory; Oxidopamine - pharmacology; Parkinson disease; Parkinson Disease, Secondary - chemically induced; Parkinson Disease, Secondary - drug therapy; Parkinson Disease, Secondary - physiopathology; Parkinson’s disease; Proteolysis; Rats; Rotation; Subtype; Synaptosomal-Associated Protein 25 - metabolism; PBS; PD; BoNT/A; ACh; ChAT; Rats; 6-OHDA; CNS; Acetylcholine; Botulinum neurotoxin; Subtype; Parkinson’s disease